1. Neuroblastoma: biological insights into a clinical enigma;Brodeur;Nat. Rev. Cancer,2003
2. The international neuroblastoma risk group (INRG) classification system: an INRG task force report;Cohn;J. Clin. Oncol.,2009
3. A.L. Yu, A.L. Gilman, M.F. Ozkaynak, W.B. London, S. Kreissman, H.X. Chen, K.K. Matthay, S.L. Cohn, J.M. Maris, P. Sondel, A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: children’s oncology group (COG) study ANBL0032, ASCO Annual Meeting, 2009 p. 15.
4. Trial watch: Immunotherapy shows promise in phase III neuroblastoma trial, Nat. Rev. Drug Discov. 8 (2009) 604.
5. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease;Lamb;Science,2006